Former President Joe Biden’s diagnosis of an aggressive, stage-4 prostate cancer has reignited a long-simmering medical debate: When should men get screened for prostate cancer? For decades, doctors have wrestled with how often to screen men for the disease and when to start and stop.

An FDA advisory committee on Wednesday unanimously voted against recommending approval of the PARP inhibitor talazoparib (Talzenna) plus enzalutamide (Xtandi) for all patients with metastatic castration-resistant prostate cancer (mCRPC).

A class of older drugs used to treat type 2 diabetes may also help slow the progression of prostate cancer, a small study suggests.

In light of former President Biden's prostate cancer diagnosis, retired journalist Jim Ware details his own journey.

Managing fatigue, sleep, urinary symptoms and depression is key to improving cognitive function in those receiving radiation therapy for prostate cancer.